Corporate Profile

Novavax, Inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines.

Recent News

  • Dec 04, 2018

    GAITHERSBURG, Md. , Dec. 04, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX) today announced the promotion of Jill Hoyt to Senior Vice President of Human Resources and Biegie Lee to Vice President of Information Technology. “I am thrilled to announce these two important management promotions;...More>>

  • Nov 12, 2018

    GAITHERSBURG, Md. , Nov. 12, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX) today announced several management promotions. “We are pleased to announce several key management promotions to further support the advancement of our company and its lead clinical programs into commercial stage,"...More>>

  • Nov 07, 2018

    Company to Host Conference Call Today at 4:30 p.m. ET GAITHERSBURG, Md. , Nov. 07, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. , (Nasdaq: NVAX) today announced its financial results and operational highlights for the third quarter and nine months ended September 30, 2018 ....More>>

Stock Quote